Lv5
1046 积分 2024-10-24 加入
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
1小时前
已关闭
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
1小时前
已完结
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study
16天前
已完结
Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease
17天前
已完结
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
30天前
已关闭
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
30天前
已完结
Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD
2个月前
已完结
Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients
3个月前
已完结
Selected biologic markers of inflammation and activity of Crohn's disease
5个月前
已完结
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
5个月前
已完结
皖公网安备34019202002308
